首页 | 本学科首页   官方微博 | 高级检索  
   检索      

耐碳青霉烯鲍曼不动杆菌的临床分布及基因组流行病学分析
引用本文:胡金树,刘伟,贾汝福,宋宇琴,王超,唐娜,冯婕.耐碳青霉烯鲍曼不动杆菌的临床分布及基因组流行病学分析[J].微生物学通报,2022,49(1):270-282.
作者姓名:胡金树  刘伟  贾汝福  宋宇琴  王超  唐娜  冯婕
作者单位:沧州市中心医院, 河北 沧州 061002;中国科学院微生物研究所, 北京 100101
基金项目:吴阶平医学基金会临床科研专项资助基金(320.6750.17533,320.6750.16050);河北省医学科学研究课题计划(20191266)
摘    要:背景]鲍曼不动杆菌是造成临床感染的重要病原菌之一,其对碳青霉烯类抗生素的耐药形势日益严重,利用基因组测序技术解析其临床分布特征和流行病学规律有助于临床感染的有效防治.目的]研究沧州市中心医院2018年检出的200株耐碳青霉烯鲍曼不动杆菌(carbapenem-resistant Acinetobacter baum...

关 键 词:耐碳青霉烯鲍曼不动杆菌  临床分布  耐药基因  基因组流行病学分析
收稿时间:2021/4/1 0:00:00

Analysis on the clinical distribution and genomic epidemiological characteristics of carbapenem-resistant Acinetobacter baumannii
HU Jinshu,LIU Wei,JIA Rufu,SONG Yuqin,WANG Chao,TANG N,FENG Jie.Analysis on the clinical distribution and genomic epidemiological characteristics of carbapenem-resistant Acinetobacter baumannii[J].Microbiology,2022,49(1):270-282.
Authors:HU Jinshu  LIU Wei  JIA Rufu  SONG Yuqin  WANG Chao  TANG N  FENG Jie
Institution:Cangzhou Central Hospital, Cangzhou 061002, Hebei, China;Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
Abstract:Background] Acinetobacter baumannii is one of the most important pathogens causing clinical infection. Its resistance level to carbapenem antibiotics is inceasing year by year. Using genome sequencing technology to analyze the distribution and epidemiological characteristics of A. baumannii can promote the effective prevention and treatment of clinical infection.Objective] To study the clinical distribution and genomic epidemiological characteristics of 200 carbapenem-resistant Acinetobacter baumannii (CRAB) strains detected in Cangzhou Central Hospital in 2018, aiming to provide a theoretical basis for the prevention of nosocomial infections and anti-infective treatment. Methods] The susceptibility of 200 CRAB strains isolated from different clinical department to 16 antimicrobial agents was detected by bacterial identification and drug sensitivity analyzer; PCR amplification was used to detect the carbapenemase gene; multi-locus sequence typing (MLST) was performed to detect strains'' sequence type; genomic epidemiological analysis revealed transmission relationships among strains from different department. Results] CRAB strains was mainly distributed in emergency ICU (47.0%), respiratory department (19.5%) and critical medicine department (12.0%). The CRAB strains showed high resistant level to imipenem, meropenem, ampicillin/sulbactam, ticacillin/clavulanic acid, gentamicin, piperacillin/tazobactam, levofloxacin, ciprofloxacin, amikacin and the third and fourth generation cephalosporins (cephalosporin, ceftriaxone and cefepime) and moderate resistance to sulfamethoxazole. Most strains were still sensitive to polymyxin B, minocycline and cefoperazone/sulbactam. The PCR results of antibiotic resistance genes showed that 180 strains (90.0%) of CRAB strains carried OXA-23 gene, 19 strains (9.5%) carried OXA-24 gene, and only 1 strain carried OXA-58 gene. The results of MLST showed that except for the OXA-58 positive strain, the others were all belonged to international clonal group CC2. Genomic epidemiology analysis showed that the strains in this hospital could be divided into four groups A, B, C and D. Group D was the main epidemic group, and it was distributed in different disease areas. Conclusions] The multidrug resistance of CRAB strain in our hospital is severe, mainly were CC2 strains carrying OXA-23 gene, and there may be infection transmission among different ward areas. The environmental cleaning work of key departments should be strengthened, the technical operation rules of medical staff should be strictly standardized, and carbapenem antibiotics should be used cautiously to reduce infection and prevent further increase of drug resistance rate.
Keywords:carbapenem-resistant Acinetobacter baumannii  clinical distribution  antibiotic resistance gene  genomic epidemiological analysis
本文献已被 维普 等数据库收录!
点击此处可从《微生物学通报》浏览原始摘要信息
点击此处可从《微生物学通报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号